Estrella Immunopharma Completes Second Dose Cohort In STARLIGHT-1 Phase I/II Clinical Trial Of EB103

Key Findings:

• The study has achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients treated in the second dose cohort.
• All patients treated are considered high-risk group who are not suitable to receive commercial CD19 products, including one with Central Nervous System (CNS) lymphoma. No treatment-related serious adverse events (SAEs) were reported during this study phase.